HeyJaredGlobalData Healthcare
- Indexed articles, last 90 days
- 4
- Latest publication
- Aug 10, 2026
- Outlet visibility, for yahoo.com
- Top 1K sites
- Earliest in this view
- Jul 29, 2026
Latest articles
FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market (opens the original)
Read excerpt
The FDA has approved Moderna's messenger RNA (mRNA) seasonal influenza vaccine, mFLUSIVA (mRNA-1010), for the prevention of seasonal influenza in adults aged 50 years and older. mFLUSIVA is now the first and only mRNA standalone seasonal influenza vaccine on the market, marking a major advancement for the field. The approval is expected to cement Moderna's position in the seasonal influenza vaccines market. Influenza vaccines produced using mRNA technology will have a shorter production time tha
European drug manufacturers under threat from proposed US supply chain bill (opens the original)
Read excerpt
Plans to investigate US reliance on overseas pharmaceutical manufacturing and supply chains are set to reveal the country's reliance on European drug manufacturing, potentially putting the region's sector at risk as the US seeks to strengthen its domestic manufacturing capabilities. One of the aims of the Pharmaceutical Investment Oversight and Accountability Act, which was re-proposed on 15 July 2026, is to promote onshoring of pharmaceutical manufacturing and discourage US reliance on foreign-
Cell and gene therapy manufacturers turn to specialist automation partners (opens the original)
Read excerpt
Cell and gene therapy manufacturers are partnering with specialist technology companies to address the challenges associated with scaling complex therapies. Recent collaborations between developers, contract development and manufacturing organisations (CDMOs), and automation companies demonstrate how robotics, digital systems, and advanced manufacturing platforms are being integrated into production workflows to support more scalable and efficient manufacturing. In June, Cellares partnered with
Dimerix acquisition of DMX-652 bolsters kidney disease development (opens the original)
Read excerpt
Dimerix, a clinical-stage biopharmaceutical company developing kidney disease treatments, recently announced that it had acquired DMX-652 from Mission Therapeutics. The acquisition adds a Phase II-ready acute kidney injury (AKI) programme with a differentiated mechanism, expanding Dimerix beyond its late-stage focal segmental glomerulosclerosis (FSGS) asset. Dimerix already has a late-stage rare kidney disease asset in FSGS, so adding DMX-652 creates a continuum from acute injury to chronic dise
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1K sites
For yahoo.com, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.